Reardon Andrew 4
4 · LIGAND PHARMACEUTICALS INC · Filed Mar 6, 2026
Research Summary
AI-generated summary of this filing
Ligand (LGND) CLO Andrew Reardon Exercises Options and Sells Shares
What Happened
- Andrew Reardon, Chief Legal Officer & Secretary of Ligand Pharmaceuticals (LGND), exercised 5,000 stock options on March 4, 2026, paying $52.27 per share (total cost $261,350) to acquire those shares. On the same day he sold 5,000 shares in multiple open-market transactions for aggregate proceeds of approximately $1,031,771.
- The Form 4 also reports a derivative line showing 5,000 shares disposed at $0 (reported as a conversion/derivative transaction). The primary economic activity reported: an option exercise followed by market sales (net proceeds ~ $1.03M). Sales were executed under a pre-established trading plan.
Key Details
- Transaction date: March 4, 2026; Form filed March 6, 2026 (timely filing).
- Exercise: 5,000 shares at $52.27 each = $261,350 (code M).
- Sales: 5,000 shares sold in multiple trades at weighted-average prices across $197.58–$208.97 (aggregate proceeds ≈ $1,031,771). Specific sale groups have weighted-average price ranges noted in the filing (see footnotes).
- Additional derivative line: 5,000 shares reported disposed at $0 (derivative conversion/disposition).
- Notable footnotes: F1 — transactions executed pursuant to a written Rule 10b5-1 trading plan adopted Nov 24, 2025; F11 — option vesting schedule noted on the filing.
- Shares owned after the transactions: not specified in the summary data provided here (refer to the Form 4 for post-transaction holdings).
Context
- This is a common pattern: an insider exercises vested options and sells the resulting shares under a prearranged 10b5-1 plan. Purchases (option exercise) indicate acquiring shares, but the immediate sales realize gains and are typically routine or for liquidity/tax purposes; the filing itself does not state motivation.
- The filing includes weighted-average sale prices and ranges (footnotes) and a derivative conversion line; for retail investors, the salient point is the exercise plus sizable sale (~$1.03M proceeds) under a 10b5-1 plan.
Insider Transaction Report
Form 4
Reardon Andrew
CLO & Secretary
Transactions
- Exercise/Conversion
Common Stock
[F1]2026-03-04$52.27/sh+5,000$261,350→ 41,869 total - Sale
Common Stock
[F1][F2]2026-03-04$197.70/sh−100$19,770→ 41,769 total - Sale
Common Stock
[F1]2026-03-04$199.00/sh−100$19,901→ 41,669 total - Sale
Common Stock
[F1][F3]2026-03-04$199.96/sh−207$41,391→ 41,462 total - Sale
Common Stock
[F1][F4]2026-03-04$200.62/sh−93$18,658→ 41,369 total - Sale
Common Stock
[F1]2026-03-04$201.70/sh−300$60,510→ 41,069 total - Sale
Common Stock
[F1][F5]2026-03-04$204.17/sh−200$40,834→ 40,869 total - Sale
Common Stock
[F1][F6]2026-03-04$205.18/sh−460$94,382→ 40,409 total - Sale
Common Stock
[F1][F7]2026-03-04$206.37/sh−340$70,165→ 40,069 total - Sale
Common Stock
[F1][F8]2026-03-04$207.01/sh−612$126,689→ 39,457 total - Sale
Common Stock
[F1][F9]2026-03-04$208.12/sh−1,446$300,939→ 38,011 total - Sale
Common Stock
[F1][F10]2026-03-04$208.87/sh−1,142$238,532→ 36,869 total - Exercise/Conversion
Employee Stock Option (right to buy)
[F1][F11]2026-03-04−5,000→ 54,444 totalExercise: $52.27Exp: 2032-08-01→ Common Stock (5,000 underlying)
Footnotes (11)
- [F1]The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 24, 2025, in accordance with Rule 10b5-1.
- [F10]The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $208.6000 to $208.9700. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F11]The stock option vests and is exercisable as to 12.5% of the underlying shares on February 1, 2023, and in 42 substantially equal monthly installments thereafter.
- [F2]The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $197.5800 to $198.3800. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $199.8800 to $200.5500. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F4]The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $200.5800 to $200.8700. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F5]The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $203.8600 to $204.4800. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F6]The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $204.8400 to $205.5700. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F7]The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $205.6000 to $206.5400. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F8]The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $206.6800 to $207.5100. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F9]The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $207.6700 to $208.5500. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Signature
/s/ Andrew Reardon|2026-03-06